Switching hormonal contraceptives to a chlormadinone acetate-containing oral contraceptive. The Contraceptive Switch Study

Schramm, Georg; Heckes, Birgit

doi:10.1016/j.contraception.2007.03.014

Cited by 25 publications

(9 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Its efficacy is probably due to a direct effect of CMA on prostaglandin synthesis, by a down-regulation of COX-2 [2,4] and a specific glucocorticoidal partial activity [2]. In one study [13], it was documented that EE/CMA is associated with a complete resolution of menstrual pain in 61.1% of switcher from other hormonal contraceptive formulations, especially in those women with frequent dysmenorrhea. In a prospective observational study carried out in 170 healthy females, a progressive and significant reduction of mild and moderate dysmenorrhea was found in the EE/CMA group in comparison to EE/DRSP group [14].…”

Section: Discussionmentioning

confidence: 96%

Effect of oral contraceptives containing estradiol and nomegestrol acetate or ethinyl-estradiol and chlormadinone acetate on primary dysmenorrhea

Grandi

Napolitano

Xholli

et al. 2015

Gynecological Endocrinology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 96%

Effect of oral contraceptives containing estradiol and nomegestrol acetate or ethinyl-estradiol and chlormadinone acetate on primary dysmenorrhea

Grandi

Napolitano

Xholli

et al. 2015

Gynecological Endocrinology

View full text Add to dashboard Cite

show abstract

“…The superiority of CMA-EE for acne improvement in comparison with other contraceptive methods has also been demonstrated in another study 20 which observed users of oral contraceptives, intrauterine devices, and intrauterine systems, who switched voluntarily to CMA-EE treatment because of dissatisfaction with their earlier contraceptive regimen. The majority of study participants (12,088, 72.0%) complained about seborrhea and/or acne while on their previous hormonal contraceptive regimen.…”

Section: Acnementioning

confidence: 76%

Efficacy, safety, and patient acceptability of the combined chlormadinone acetate-ethinylestradiol oral contraceptive

Ferrari¹,

Cannoletta²,

Generali

et al. 2010

OAJC

View full text Add to dashboard Cite

Since their introduction in 1959, development of hormonal contraceptives has been ongoing, with the ultimate aim of creating not only an effective and safe contraceptive method, but also a drug able to meet the need for treatment of other conditions, such as acne, seborrhea, and hirsutism, with few or no side effects. With this objective, a new progestin, chlormadinone acetate (CMA), has been developed as a derivative of progesterone for contraception. This new molecule has been introduced in combination with ethinylestradiol (EE) 30 µg as a safe contraceptive with antiandrogenic properties. Many clinical studies have investigated this new oral combination and found it to be safe, with a Pearl Index similar to that of other combined hormonal contraceptives. CMA, because of its antiandrogenic properties, has been also considered effective for resolution of acne, seborrhea, and hirsutism. The data show it to be a safe molecule in terms of glucose and lipid metabolism. No major weight changes have been linked with its use, and it seems to be the only progestin able to reduce fat mass during use. The CMA-EE combination is well tolerated and acceptable to women. Adverse events related to its use are similar to those reported with other third-generation contraceptives. We can conclude that CMA-EE is an effective, safe, and well tolerated antiandrogenic hormonal contraceptive.

show abstract

“…[25,26] Many other non-comparative and or observational studies investigating the contraceptive efficacy of EE CMA support data from the previously mentioned well-designed trials. [34,[36][37][38][39][40] These clinical trials are summarized in table I.…”

Section: Seborrheamentioning

confidence: 99%

“…[29] Data from uncontrolled clinical trials investigating the contraceptive efficacy of EE CMA in women that support the possible effect of EE CMA in patients with seborrhea are presented in table I. [25,26,34,37,38,40] Taken together, these limited data suggest that EE CMA may be effective for the management of seborrhea; however, further examination of EE CMA in seborrhea is required.…”

Section: Ethinylestradiol Chlormadinone Acetate In Seborrheamentioning

confidence: 99%

Ethinylestradiol/Chlormadinone Acetate

Guerra‐Tapia¹,

Pérez²

2011

American Journal of Clinical Dermatology

View full text Add to dashboard Cite

Acne vulgaris, hirsutism, seborrhea and female pattern hair loss (FPHL) are common disorders of the pilosebaceous unit (PSU). In some women with hyperandrogenemia, an excess of androgens at the PSU can lead to the development of these dermatological manifestations. These manifestations can cause many psychiatric and psychological implications, such as social fears and anxiety, and can adversely affect quality of life. High androgen levels at the PSU as a possible underlying cause of acne vulgaris, hirsutism, seborrhea and FPHL supports the rationale for using combined oral contraceptives for the management of these conditions in women. The purpose of this review is to describe these dermatological manifestations of the PSU and the management of these conditions through the use of the oral contraceptive ethinylestradiol/chlormadinone acetate (EE/CMA). EE/CMA 0.03/2 mg is a combined monophasic contraceptive pill with anti-androgenic properties. It is approved in Europe for contraception and has been investigated in phase III trials for the treatment of acne. EE/CMA was better than placebo and similar to another low-dose oral contraceptive (ethinylestradiol/levonorgestrel) in improving symptoms of acne in two phase III randomized controlled trials in patients with mild to moderate papulopustular acne. In addition, in trials investigating the contraceptive efficacy of EE/CMA, limited data suggest that there were also improvements in hirsutism, FPHL and seborrhea in small subgroups of patients. EE/CMA has a good safety profile. The most commonly reported adverse events are breast tenderness/pain, headache/migraine and nausea. Evidence in the literature indicates that the use of EE/CMA for the treatment of dermatological disorders under the control of androgens may be a valid treatment option. Further investigation is warranted.

show abstract

Switching hormonal contraceptives to a chlormadinone acetate-containing oral contraceptive. The Contraceptive Switch Study

Cited by 25 publications

References 27 publications

Effect of oral contraceptives containing estradiol and nomegestrol acetate or ethinyl-estradiol and chlormadinone acetate on primary dysmenorrhea

Effect of oral contraceptives containing estradiol and nomegestrol acetate or ethinyl-estradiol and chlormadinone acetate on primary dysmenorrhea

Efficacy, safety, and patient acceptability of the combined chlormadinone acetate-ethinylestradiol oral contraceptive

Ethinylestradiol/Chlormadinone Acetate

Contact Info

Product

Resources

About